US-based Gestalt Diagnostics has completed a Series A financing round, raising $7.5m for expanding its AI-powered PathFlow pathology platform.
The funding will also enable wider market adoption and platform profitability.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
TVF Funds, Inland Imaging Investments, Cowles Ventures and KickStart Funds led the financing round, which included participation from Pacific Northwest investors.
The capital injection will be used to widen the company’s customer base, improve its AI offerings, and help enable clearance from the US Food and Drug Administration (FDA).
PathFlow is adopted by healthcare providers, research organisations and academic medical centres for its integration with their current lab information systems.
This integration expedites diagnoses and enhances access to consultation, research and education, irrespective of the location.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataAccording to Gestalt, the platform not only accelerates the processes crucial for cancer patients awaiting diagnoses but also offers AI-powered insights.
These insights facilitate biomarker scoring for patient-therapy matching.
They also enable analysis of images and data for disease progression studies and provide pathologists with valuable aids that streamline workflows and decrease diagnostic errors.
Gestalt’s PathFlow V5.0 employs several latest features, including the capability to conduct AI-based image analysis using various AI partners simultaneously.
The outcomes can be retrieved and displayed on PathFlow’s viewer. On demand, the data from various algorithms can be switched.
The platform also includes secure e-signature capabilities for report sign-out through digital signature provider DocuSign and also has a Voicebrook integration.
It facilitates automatic upload of digital assets directly to cases.
Gestalt Diagnostics CEO Dan Roark said: “PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organisations to accurately match patients to known therapies and generate rich datasets for research and new drug development.
“Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise.”
